Roivant Sciences (ROIV) said Thursday it has fast-tracked four of its key drug development programs.

The new drug application filing for Brepocitinib in dermatomyositis is now expected early next year, with a commercial launch expected in early 2027. The company said its phase 3 trial for the drug candidate in non-infectious uveitis is fully enrolled, with topline data now expected in H2 2026.

Meanwhile, the Brepocitinib proof-of-concept trial in cutaneous sarcoidosis is fully enrolled, with topline data expected in H1 2026.

For the IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis, topline data are now expected next year, the company said.

Roivant also said it led a funding round for Immunovant (IMVT) that garnered gross proceeds of around $550 million. The funding will extend Immunovant's cash runway to the launch of IMVT-1402 in Graves' disease.